Security
PlasmaTech Biopharmaceuticals, Inc. Common Stock · PTBI
PTBIOTCCommon stockHistorical · closed Nov 24, 2014CIK 318306Updated Nov 19, 2026
PTBI price & chart
This listing closed Nov 24, 2014. Live provider charts are shown only for current listings.
Current security: ABEO
About the company
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
In the news
No coverage from other publishers is available.
Recent filings
S-3 filing
SCHEDULE 13G - filed by Rubric Capital Management LP regarding ABEONA THERAPEUTICS INC.
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.01, 3.02, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 231,095,000Source | 120,592,000Source | 179,507,000Source | 246,233,000Source | 134,003,000Source | 198,494,000Source | 99,364,000Source | 74,828,000Source | 219,570,000Source | 108,931,000Source | 64,002,000Source | 64,214,000Source |
| Property, Plant and Equipment, NetUSD | 10,338,000Source | 4,058,000Source | 10,152,000Source | 9,489,000Source | 3,975,000Source | 10,564,000Source | 6,947,000Source | 3,767,000Source | 9,921,000Source | 4,430,000Source | 3,533,000Source | 5,741,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 82,884,000Source | 15,726,000Source | 56,229,000Source | 163,535,000Source | 34,426,000Source | 61,374,000Source | 15,936,000Source | 17,558,000Source | 78,437,000Source | 23,357,000Source | 14,473,000Source | 14,217,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 9,394,000Source | — | — | 6,200,000Source | — | — | 6,147,000Source | — | — | — |
| Inventory, NetUSD | 4,850,000Source | — | 5,921,000Source | 2,686,000Source | — | 6,054,000Source | — | — | 5,493,000Source | — | — | — |
| Assets, CurrentUSD | 216,130,000Source | 112,657,000Source | 164,578,000Source | 232,262,000Source | 125,904,000Source | 182,985,000Source | 88,121,000Source | 66,725,000Source | 204,906,000Source | 100,853,000Source | 55,737,000Source | 53,099,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,209,000Source | 1,005,000Source | 1,942,000Source | 2,090,000Source | 1,218,000Source | 1,951,000Source | 2,011,000Source | 1,811,000Source | 1,294,000Source | 1,143,000Source | 729,000Source | 424,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,086,000Source | 3,789,000Source | 3,950,000Source | 4,144,000Source | 4,024,000Source | 4,118,000Source | 4,239,000Source | 4,222,000Source | 3,962,000Source | 3,552,000Source | 4,455,000Source | 5,331,000Source |
| Other Assets, NoncurrentUSD | 541,000Source | 88,000Source | 827,000Source | 338,000Source | 100,000Source | 827,000Source | 57,000Source | 114,000Source | 781,000Source | 96,000Source | 277,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 59,862,000Source | 74,819,000Source | 51,449,000Source | 82,657,000Source | 60,762,000Source | 53,555,000Source | 57,968,000Source | 83,709,000Source | 60,354,000Source | 64,900,000Source | 49,176,000Source | 37,453,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 524,000Source | 434,000Source | 572,000Source | 512,000Source | 417,000Source | 568,000Source | 490,000Source | 276,000Source | 550,000Source | 457,000Source | 265,000Source | 177,000Source |
| Additional Paid in CapitalUSD | 892,314,000Source | 849,388,000Source | 906,906,000Source | 879,563,000Source | 846,654,000Source | 903,542,000Source | 866,260,000Source | 772,129,000Source | 900,603,000Source | 856,824,000Source | 764,151,000Source | 722,049,000Source |
| Retained Earnings (Accumulated Deficit)USD | -721,615,000Source | -803,965,000Source | -779,341,000Source | -716,454,000Source | -773,696,000Source | -759,150,000Source | -825,287,000Source | -781,102,000Source | -742,075,000Source | -813,258,000Source | -749,524,000Source | -695,336,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 10,000Source | -84,000Source | -79,000Source | -45,000Source | -134,000Source | -21,000Source | -67,000Source | -184,000Source | 138,000Source | 8,000Source | -66,000Source | -129,000Source |
| Stockholders' Equity Attributable to ParentUSD | 171,233,000Source | 45,773,000Source | 128,058,000Source | 163,576,000Source | 73,241,000Source | 144,939,000Source | 41,396,000Source | -8,881,000Source | 159,216,000Source | 44,031,000Source | 14,826,000Source | 26,761,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 7,000,000Source |
| Liabilities and EquityUSD | 231,095,000Source | 120,592,000Source | 179,507,000Source | 246,233,000Source | 134,003,000Source | 198,494,000Source | 99,364,000Source | 74,828,000Source | 219,570,000Source | 108,931,000Source | 64,002,000Source | 64,214,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 22,180,000Source | 18,422,000Source | 24,806,000Source | 34,517,000Source | 16,843,000Source | 31,046,000Source | 17,983,000Source | 11,889,000Source | 29,570,000Source | 16,587,000Source | 13,422,000Source | 7,779,000Source |
| Operating Lease, Liability, CurrentUSD | 102,000Source | 1,057,000Source | 1,280,000Source | 537,000Source | 1,792,000Source | 1,272,000Source | 613,000Source | 1,044,000Source | 864,000Source | 823,000Source | 998,000Source | 1,773,000Source |
| Accounts Payable, CurrentUSD | 5,927,000Source | 2,789,000Source | 2,994,000Source | 7,337,000Source | 3,099,000Source | 4,071,000Source | 5,018,000Source | 3,362,000Source | 7,889,000Source | 3,441,000Source | 1,858,000Source | 1,811,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,254,000Source | 3,402,000Source | 3,604,000Source | 3,978,000Source | 3,018,000Source | 3,814,000Source | 4,078,000Source | 4,046,000Source | 4,069,000Source | 3,262,000Source | 4,402,000Source | 5,854,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | — | — | — | — | — | 3Source | — | — | — |
| Accrued Liabilities, CurrentUSD | 6,888,000Source | 5,210,000Source | 7,197,000Source | 5,495,000Source | 4,924,000Source | 5,368,000Source | 3,887,000Source | 2,791,000Source | 8,467,000Source | 6,333,000Source | 5,985,000Source | 3,991,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 110,000,000Source | — | — | 123,000,000Source | — | 84,500,000Source | 62,700,000Source | — | 98,100,000Source | 52,600,000Source | 52,500,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,604,000Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | — |
| Long-term Debt, Current MaturitiesUSD | 8,889,000Source | 4,444,000Source | 13,333,000Source | 5,556,000Source | 2,222,000Source | 13,333,000Source | 8,148,000Source | — | 12,222,000Source | 5,926,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 10,862,000Source | 14,206,000Source | 1,655,000Source | 14,005,000Source | 16,133,000Source | 4,754,000Source | 11,138,000Source | 18,079,000Source | 7,813,000Source | 13,037,000Source | — | — |
| Short-term InvestmentsUSD | 124,233,000Source | 93,975,000Source | 90,597,000Source | 61,983,000Source | 88,282,000Source | 106,897,000Source | 68,219,000Source | 44,786,000Source | 112,967,000Source | 74,363,000Source | 37,753,000Source | 37,932,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 690,000Source | 534,000Source | 2,549,000Source | 2,004,000Source | 2,288,000Source | 3,093,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,957,000Source | 2,701,000Source | 10,779,000Source | 6,628,000Source | 4,768,000Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 53,000Source | — | 6,147,000Source | — | — | -3,000,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 561,000Source | — | 5,493,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -19,804,000Source | -18,402,000Source | -76,326,000Source | -56,015,000Source | -37,009,000Source | -43,483,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 4,963,000Source | 4,213,000Source | 105,028,000Source | -39,240,000Source | 208,000Source | -23,964,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 935,000Source | 1,401,000Source | 7,975,000Source | 2,446,000Source | 331,000Source | 130,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -2,222,000Source | 6,768,000Source | 26,040,000Source | 104,139,000Source | 37,057,000Source | 43,173,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -17,063,000Source | -7,421,000Source | 54,742,000Source | 8,884,000Source | 256,000Source | -24,274,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 83,222,000Source | 16,064,000Source | 56,229,000Source | 163,873,000Source | 61,374,000Source | 16,274,000Source | 78,437,000Source | 23,695,000Source | 14,811,000Source | 14,555,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 555,000Source | 675,000Source | 2,589,000Source | 2,670,000Source | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | 7,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,689,000Source | 1,804,000Source | 3,369,000Source | 2,830,000Source | 2,957,000Source | 2,701,000Source | 10,779,000Source | 6,628,000Source | 4,768,000Source | 3,051,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 110,000,000Source | — | — | — | 84,500,000Source | — | 98,100,000Source | 52,600,000Source | 52,500,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 2,000Source | -47,000Source | -138,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | — | 292,000Source |
| General and Administrative ExpenseUSD | — | — | — | 6,404,000Source | — | — | 19,502,000Source | 9,786,000Source | 65,031,000Source | 29,851,000Source | 19,004,000Source | 17,256,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 1,355,000Source |
| Income Tax Expense (Benefit)USD | — | — | -15,197,000Source | — | — | 15,512,000Source | 2,000Source | — | 100,000Source | — | — | — |
| Inventory Write-downUSD | — | — | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,161,000Source | -30,269,000Source | -20,191,000Source | 108,833,000Source | -17,075,000Source | -12,029,000Source | 71,183,000Source | -63,734,000Source | -54,188,000Source | -39,696,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | -12,000,000Source | — | -63,700,000Source | -54,188,000Source | -43,478,000Source |
| Nonoperating Income (Expense)USD | — | — | 129,000Source | 145,000Source | -6,000Source | 89,000Source | 50,000Source | 141,000Source | 410,000Source | 1,194,000Source | 2,943,000Source | — |
| Operating ExpensesUSD | — | — | — | 15,345,000Source | — | 23,192,000Source | — | 19,727,000Source | — | 64,211,000Source | 50,635,000Source | 52,329,000Source |
| Operating Lease, ExpenseUSD | — | — | 400,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 400,000Source | 1,700,000Source | 1,300,000Source | 1,200,000Source | — |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | -1,065,000Source | 2,511,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 6,799,000Source | 17,300,000Source | 15,475,000Source | 14,408,000Source | 12,839,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 20,000,000Source | — | — |
| Repayments of Long-term Debt | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 11,380,000Source | 400,000Source | 8,720,000Source | — | 5,820,000Source | — | 3,500,000Source | 1,414,000Source |
| Cost of RevenueUSD | — | — | 488,000Source | — | 4,177,000Source | — | 2,696,000Source | — | 1,532,000Source | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 19,314,000Source | 6,404,000Source | 15,835,000Source | 17,149,000Source | 19,502,000Source | 9,786,000Source | 65,031,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | -24,018,000Source | -15,345,000Source | -13,653,000Source | -22,792,000Source | -23,033,000Source | -19,727,000Source | -89,448,000Source | -64,211,000Source | -47,135,000Source | -50,915,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -20,358,000Source | -30,269,000Source | -20,191,000Source | 124,345,000Source | -17,073,000Source | -12,029,000Source | 71,283,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | -15,197,000Source | — | — | 15,512,000Source | 2,000Source | — | 100,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,161,000Source | -30,269,000Source | -20,191,000Source | 108,833,000Source | -17,075,000Source | -12,029,000Source | 71,183,000Source | -63,734,000Source | -54,188,000Source | -39,696,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.1Source | -0.63Source | -0.35Source | 2.07Source | -0.3Source | -0.24Source | 1.34Source | -1.55Source | -2.53Source | -5.53Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.1Source | -0.63Source | -0.35Source | 1.71Source | -0.3Source | -0.24Source | 1.01Source | -1.55Source | -2.53Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 54,242,507Source | 48,081,758Source | 57,048,385Source | 52,524,510Source | 56,620,920Source | 49,778,801Source | 52,952,917Source | 41,048,206Source | 21,380,476Source | 7,861,515Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 54,242,507Source | 48,081,758Source | 57,048,385Source | 66,640,620Source | 56,620,920Source | 49,778,801Source | 66,135,821Source | 41,048,206Source | 21,380,476Source | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 24,018,000Source | 15,345,000Source | 25,033,000Source | 23,192,000Source | 31,753,000Source | 19,727,000Source | 95,268,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | 15,200,000Source | 0Source | — | 15,500,000Source | — | — | 100,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 600,000Source | 500,000Source | 700,000Source | 600,000Source | 700,000Source | 500,000Source | 2,500,000Source | 2,000,000Source | 2,300,000Source | 3,100,000Source |
| General and Administrative ExpenseUSD | — | — | — | 6,404,000Source | — | — | 19,502,000Source | 9,786,000Source | 65,031,000Source | 29,851,000Source | 19,004,000Source | 17,256,000Source |
| Interest ExpenseUSD | — | — | 901,000Source | 1,102,000Source | 696,000Source | 957,000Source | 830,000Source | 998,000Source | 3,740,000Source | 4,208,000Source | 418,000Source | 736,000Source |
| Interest Income, OperatingUSD | — | — | 1,672,000Source | 1,189,000Source | 1,355,000Source | 1,027,000Source | 1,354,000Source | 1,310,000Source | 5,556,000Source | 4,246,000Source | 2,117,000Source | 431,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | -12,000,000Source | — | -63,700,000Source | -54,188,000Source | -43,478,000Source |
| Nonoperating Income (Expense)USD | — | — | 129,000Source | 145,000Source | -6,000Source | 89,000Source | 50,000Source | 141,000Source | 410,000Source | 1,194,000Source | 2,943,000Source | — |
| Operating ExpensesUSD | — | — | — | 15,345,000Source | — | 23,192,000Source | — | 19,727,000Source | — | 64,211,000Source | 50,635,000Source | 52,329,000Source |
| Operating Lease, ExpenseUSD | — | — | 400,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 400,000Source | 1,700,000Source | 1,300,000Source | 1,200,000Source | — |
| Other Operating IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 141,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 3,782,000Source |
| Research and Development ExpenseUSD | — | — | 4,216,000Source | 8,941,000Source | 5,021,000Source | 5,943,000Source | 9,555,000Source | 9,941,000Source | 26,812,000Source | 34,360,000Source | 31,091,000Source | 28,965,000Source |
Offerings
Registration 333-300134
Filing attachments
ex107.htm · S-3 · 2026-11-18
Calculation of Filing Fee Tables S-3 ABEONA THERAPEUTICS INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri…
Read attachment ↗tm2629604d1_ex99-1.htm · SCHEDULE 13G · 2026-11-16
EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress - Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 - - 15 ZEVASKYN treatments completed since launch, including six during Q3 - - QTC network expanded to eight sites; four centers have completed patient treatments - - ZEVASKYN NTAP status became effective October 1, 2026 - - $134.9 million in cash, cash equivalents and short-term investments as of Septembe…
Read attachment ↗ex4-1.htm · 8-K · 2026-11-09
Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 6, 2026, is entered into by and between Abeona Therapeutics Inc., a Delaware corporation (the “Company”), and Ellodi Pharmaceuticals, L.P., a Delaware limited partnership (the “Initial Seller” and, together with its permitted assigns under Section 8, the “Sellers,” and each, a “Seller”). “Investor” means a Seller, and “Investors” means the Sellers. Capitalized terms used herein…
Read attachment ↗ex4-2.htm · 8-K · 2026-11-09
Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATOINS THEREUNDER (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT,…
Read attachment ↗